2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Practice Models, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Elderly
PAPER

3702 Time to next treatment (TTNT) after bispecific antibody (BsAb) treatment in aggressive large B-cell lymphoma (LBCL) patients (Pts): A collaborative US bispecifics consortium (CUBIC) analysis

Cassandra Duarte, MD, Reid W Merryman, MD2, Jennifer L. Crombie, MD3, Lorenzo Falchi, MD4, Geoffrey Shouse, DO PhD5, Swetha Kambhampati Thiruvengadam6, Matthew A. Lunning, DO, FACP7, Allison Marie Bock, MD8, Shannon M. Buckley, PhD9, Steven Bair, MD10, Ajay Major, MD, MBA11, Andrew P. Jallouk, MD, PhD12, Shakthi P. Bhaskar, MD13, Yazeed Sawalha, MD14, Narendranath Epperla, MD, MS, FACP15, Ayushi Chauhan, MD16, Alexey V. Danilov, MD, PhD17, Gulrayz Ahmed, MD18, Mehdi Hamadani, MD19, Gilles Salles I, MD, PhD20, Christopher R. Flowers Jr, MD, MS21, Amy A. Ayers22, Alex Francisco Herrera, MD23, Chijioke C Nze, MD, MPH24, Sairah Ahmed, MD25
1 The University of Colorado, Aurora, Colorado, United States
2 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
3 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
4 Memorial Sloan Kettering Cancer Center, New York, New York, United States
5 City of Hope, Duarte, California, United States
6 City of Hope, Duarte, California, United States
7 University of Nebraska Medical Center, Omaha, Nebraska, United States
8 Huntsman Cancer Institute, Salt Lake City, Utah, United States
9 Huntsman Cancer Institute, Salt Lake City, Utah, United States
10 The University of Colorado, Aurora, Colorado, United States
11 The University of Colorado, Aurora, Colorado, United States
12 Vanderbilt University Medical Center, Nashville, Tennessee, United States
13 Vanderbilt University Medical Center, Nashville, Tennessee, United States
14 Ohio State University, Columbus, Ohio, United States
15 Huntsman Cancer Institute, Salt Lake City, Utah, United States
16 MD Anderson Cancer Center, Houston, Texas, United States
17 City of Hope, Duarte, California, United States
18 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
19 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
20 Memorial Sloan Kettering Cancer Center, New York, New York, United States
21 MD Anderson Cancer Center, Houston, Texas, United States
22 MD Anderson Cancer Center, Houston, Texas, United States
23 City of Hope, Duarte, California, United States
24 MD Anderson Cancer Center, Houston, Texas, United States
25 MD Anderson Cancer Center, Houston, Texas, United States

Introduction: BsAbs including epcoritamab (epco) and glofitamab (glofit) represent a transformative therapeutic approach for LBCL pts. Limited real-world data are available regarding TTNT following bispecific antibody therapy in patients with LBCL, particularly given that glofit is administered for a fixed duration, whereas epco is continued until disease progression or unacceptable toxicity. We present the first real world analysis of TTNT after BsAb therapy for LBCL pts undergoing treatment with epco or glofit.

Methods: A retrospective multicenter study using CUBIC data was conducted of adult pts with LBCL who received at least one dose of epco or glofit as monotherapy or in combination with radiation. Primary outcome was TTNT either for monotherapy or combination therapy with radiation (RT). TTNT is defined as time from initiation of BsAb to the earliest occurrence of either initiation of next systemic therapy or death from any cause. Pts who were alive and had not initiated next line of treatment were censored. Secondary outcomes included overall response rate (ORR) and complete response rate (CRR). Univariable and multivariable analysis was conducted to assess factors impacting TTNT and ORR. Kaplan-Meier curves were generated to estimate TTNT for treatment groups and differences between the groups were assessed using a log-rank test.

Results: 233 pts met study criteria. The study population had a median age of diagnosis of 67 years, was 82% (n=185) White, 12% (27) Hispanic, and 65% (151) male. 82% (192) had DLBCL histology and 12% (27) had double hit LBCL. At diagnosis 87% (174) of pts were advanced stage with 43% (90) non-germinal center/ABC subtype, 20% (37) with bulky disease (>7.5cm), and 63% (145) with elevated LDH. 69% (115) had high-intermediate/high International Prognostic Index (IPI) scores. Pts had a median of 3 lines (range 1-11) of therapy prior to BsAb. 96% (213) received BsAb monotherapy (47% [101] glofit, 53% [112] epco). Of the 20 pts receiving combination therapy, 55% (11) received epco+RT and 45% (9) received glofit+RT. 40% (90) of pts had progressive disease to last therapy before BsAb, 54% (125) had prior CAR T cell therapy and 8% (18) had prior autologous stem cell transplant. There was no statistically significant difference in characteristics between monotherapy arms or combination therapy arms.

With a median follow up time of 12.8 months (95% CI 11.5-14.9), there was no statistically significant difference in TTNT between epco (3.2 months [mo]) and glofit monotherapy (4mo) (p=0.06). For pts receiving BsAb with RT, TTNT was 4.4mo for epco+RT and 7.8mo for glofit+RT (p=0.11).

ORR for epco monotherapy was 42.4% (25% CRR), epco+RT was 36.4% (18% CR), glofit monotherapy 53.4% (39% CR) and glofit+RT 44.4% (33% CR). 63% of epco monotherapy pts experienced progression to BsAb versus 54% of glofit monotherapy patients. Cause of death in pts who received epco monotherapy was lymphoma progression in 77%, treatment related infection in 9.5%, and other non-lymphoma causes in 10.8%. Cause of death in pts who received glofit monotherapy was lymphoma progression in 88%, and other non-lymphoma causes in 10%.

Univariable analysis demonstrated that advanced stage (hazard ratio [HR] 1.98), IPI score ≥3 (HR 2.53), elevated LDH (HR 2.44), bulky disease (HR 1.65) and ECOG ≥2 (HR 1.58) at diagnosis were all associated with shorter TTNT (p ≤0.05). With multivariable analysis only elevated LDH had significance for TTNT (HR 2.47, p <0.001).Univariable analysis identified IPI score ≥3 (HR 0.53), elevated LDH (0.47), ECOG ≥2 (0.53), and prior CAR T (HR 1.87) were significant with ORR. Multivariable analysis identified no statistically significant variables associated with inferior ORR.

Additional analyses on BsAb discontinuation (i.e, progression, infection, adverse events) and TTNT for BsAb responders will be presented at ASH Conference.

Discussion: To our knowledge, this is the first study evaluating TTNT in LBCL pts on BsAb therapy. TTNT is an important endpoint that may reflect disease control and treatment-related toxicity. Despite differences in administration—fixed-duration with glofit versus treatment until progression with epco—there was no statistically significant difference in TTNT among pts receiving BsAb as monotherapy or in combination with RT, suggesting dosing schedule did not affect TTNT.

Cassandra Duarte, MD: Cogent Biosciences - Honoraria; EMD Serono - Honoraria; Electra Therapeutics - Research Funding; Blueprint Medicine - Research Funding; Cogent Biosciences - Consultancy (Includes expert testimony)